Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nuvo Announces Notice of Intention to Grant a European Patent for PENNSAID® 2%

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
Patent applications currently pending in Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan and Mexico.

Nuvo Research Inc. has announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID® 2% product.

Upon grant by the European Patent Office, the patent can be officially validated in over 37 European countries.

PENNSAID 2% is protected by issued patents in the United States expiring April 21, 2028 and in New Zealand, South Africa and the Russian Federation with an expiration date of October 17, 2027.

Patent applications covering PENNSAID 2% are currently pending in Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan and Mexico and have an anticipated expiry date of October 17, 2027.

The Company is currently in discussions with potential marketing partners interested in licensing PENNSAID and/or PENNSAID 2% for Europe, Russia, China, the Middle East, Asia and Australia.

"We are very pleased with the progress we are making to secure worldwide patent protection for our next generation topical NSAID, PENNSAID 2%," said Tina Loucaides, Nuvo's Vice-President and General Counsel.

Loucaides continued, "This expanding patent portfolio supports our efforts to secure international licensing partners for PENNSAID 2% and additional sources of revenue for Nuvo."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nuvo Research Announces Collaboration to Develop Topical Dermatology Products
Company will utilize its proprietary MMPE technology to formulate topical dermatology products.
Saturday, April 26, 2014
Nuvo Research Announces 2013 Fourth Quarter & Year-End Results
Company will commence a Phase 2 study of WF10 with results expected in Q4 2014.
Friday, March 07, 2014
Nuvo Research® and NovaMedica Sign Agreement to Market Pennsaid® in Russia
Sales of Pennsaid 1.5% in Russia to begin in 2015.
Monday, December 23, 2013
Nuvo Research Announces Scientific Presentation at the Annual Meeting of AAI
Data evaluating WF10's therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice.
Friday, May 17, 2013
Nuvo Granted U.S. Patent for Using WF10
New derivative formulations for the treatment of Allergic Rhinitis and Allergic Asthma.
Thursday, May 16, 2013
Nuvo Research Announces New Listing of Synera® Patent in FDA Orange Book
The Synera Patent expiry date is July 7, 2020.
Thursday, December 27, 2012
Nuvo Research Receives €4.4 Million Additional Funding to Develop WF10
Total cost of the development program is estimated to be €6.3 million.
Thursday, December 27, 2012
Nuvo Research Announces 2012 Second Quarter Results
Company receives notice of a positive opinion for the approval of Pliaglis.
Tuesday, August 07, 2012
Nuvo Research to Receive US$6.0 Million of Milestone Payments from Pliaglis® E.U. Approvals
Nuvo to launch Pliaglis in the E.U. and other territories in the first half of 2013.
Friday, July 20, 2012
Nuvo Research Provides PENNSAID® Commercial Update
U.S. licensee resumes distribution of PENNSAID sample bottles.
Monday, June 18, 2012
Pliaglis Receives Positive Opinion from the BfArM in the E.U.
Enters national licensing phase in 17 E.U. countries.
Tuesday, May 08, 2012
Nuvo Research Announces 2012 First Quarter Results
U.S. prescriptions of Pennsaid continued to grow quarter-over-quarter.
Thursday, May 03, 2012
Nuvo Research Announces Management Change
Stephen L. Lemieux to become Vice President and Chief Financial Officer of Nuvo Research.
Monday, February 13, 2012
Nuvo Research U.S. Awarded US$1.3 Million in Research Grants
The grants were awarded for 2009 and 2010 research programs relating to topical and transdermal formulations.
Thursday, November 11, 2010
Nuvo Research Announces Positive Top-Line WF10 Phase II Trial Results
European Phase II clinical trial evaluating WF10 as a treatment for severe allergic rhinitis meets its primary endpoint.
Tuesday, November 09, 2010
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Automated Patch Clamping Trends
Learn more about current practices, preferences and metrics in ion channel drug screening using APC technology.
Lab-on-a-Stick: Miniaturised Clinical Testing For Fast Detection Of Antibiotic Resistance
A portable power-free test for the rapid detection of bacterial resistance to antibiotics has been developed by academics at Loughborough University and the University of Reading.
Genetic Ancestry of Cultivated Strawberry Unravelled
UNH scientists constructed a linkage map of the seven chromosomes of the diploid Fragaria iinumae, which allows them to fill in a piece of the genetic puzzle about the eight sets of chromosomes of the cultivated strawberry.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
New Drug Target for Inflammatory Disorders
Penn study finds enigmatic molecules maintain equilibrium between fighting infection and inflammatory havoc.
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Mechanisms of Calcium Blockers
Researchers describe how the fundamental mode of action of two distinct chemical classes of calcium channel blockers differs.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!